You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse
|
|---|---|
| Published in |
Leukemia & Lymphoma, September 2017
|
| DOI | 10.1080/10428194.2017.1375107 |
| Pubmed ID | |
| Authors |
Katherine D. Cummins, Saar Gill |
| Abstract |
Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted immunotherapy which have induced remissions in some patients with chemotherapy refractory or relapsed (RR) hematologic malignancies. Hundreds of patients have now been treated worldwide with anti-CD19 CART cells, with complete response rates of up to 90%. CART therapy has a unique toxicity profile, and unfortunately not all responses are durable. Treatment failure occurs via two main routes - by loss of the CART cell population, or relapse with antigen loss. Emerging data indicate that targeting an alternative antigen instead of, or as well as CD19, could improve CART cell efficacy and reduce antigen-negative relapse. Other strategies include the addition of other immune-based therapies. This review explores the rationale, pre-clinical data and currently investigative strategies underway for CART therapy targeting the myeloid and lymphoid stem/progenitor antigen CD123. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 76 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 12 | 16% |
| Student > Ph. D. Student | 11 | 14% |
| Researcher | 11 | 14% |
| Student > Master | 11 | 14% |
| Other | 8 | 11% |
| Other | 9 | 12% |
| Unknown | 14 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 30% |
| Biochemistry, Genetics and Molecular Biology | 16 | 21% |
| Agricultural and Biological Sciences | 6 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Nursing and Health Professions | 3 | 4% |
| Other | 5 | 7% |
| Unknown | 18 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2018.
All research outputs
#18,572,036
of 23,002,898 outputs
Outputs from Leukemia & Lymphoma
#2,848
of 4,017 outputs
Outputs of similar age
#242,649
of 316,290 outputs
Outputs of similar age from Leukemia & Lymphoma
#39
of 64 outputs
Altmetric has tracked 23,002,898 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,017 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,290 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.